港股異動丨蒙牛乳業漲3.39% 貝拉米收購案取得進展
格隆匯10月31日丨蒙牛乳業漲3.39%,報32.05港元,成交9385萬港元,總市值1260億港元。

有機嬰幼兒配方奶粉及嬰兒食品廠商貝拉米在週三澳大利亞股市收盤後發佈公告稱,新南威爾士州最高法院已經批准將關於蒙牛收購貝拉米的計劃書分發給股東。此外,該最高法院還命令貝拉米召開股東大會,對收購計劃進行討論和投票,會議日期為12月5日。按照計劃,收購計劃書將於週四在ASIC備案並在澳交所公佈。隨後,計劃書、獨立專家報告以及會議通知將於11月4日發送給股東。如果股東大會通過收購計劃,則表明大多數障礙被清除,但仍需獲得澳大利亞外國投資審批委員會的批准。分析人士指出,貝拉米的公告意味着該收購案向前邁出重要一步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.